Follow The Filings

LENZ LENZ Therapeutics

LENZ Therapeutics earnings company data as of 6:59 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by LENZ's executives, directors and 10% owners in the last 12 months, from their Form 4s

All LENZ insider trades
  • $655K bought by 4 insiders
  • None no sales outside a trading plan
  • $261K sold by 1 insider under 10b5-1 plans
  1. Jeffrey P. George Director
    Buy
    $50K 5,592 shares at $8.92 New stake
    Traded Mar 27 Filed Mar 30
  2. Evert B. Schimmelpennink CEO
    Buy
    $251K 28,089 shares at $8.95 +57% to stake
    Traded Mar 27 Filed Mar 30
  3. Daniel R. Chevallard CFO
    Buy
    $64K 7,500 shares at $8.57 +139% to stake
    Traded Mar 27 Filed Mar 30
  4. Shawn Olsson Chief Commercial Officer
    Planned sale
    $261K 10,000 shares at $26.10 68% of stake
    Traded Nov 17, 2025 Filed Nov 19, 2025
  5. James W McCollum Director
    Buy
    $239K 10,500 shares at $22.79 New stake
    Traded Nov 7, 2025 Filed Nov 10, 2025
  6. Daniel R. Chevallard CFO
    Buy
    $50K 2,198 shares at $22.76 +69% to stake
    Traded Nov 7, 2025 Filed Nov 7, 2025

Also filed in the last 12 months, not counted as buying or selling: 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 23 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
8-K 5.02
SCHEDULE 13G —
8-K 5.07
8-K 2.02,9.01
10-Q
DEF 14A
DEFA14A
SCHEDULE 13G —
SCHEDULE 13G —
8-K 2.02,9.01
10-K
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
8-K 8.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13D/A —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.